Effect of long-term blockade of CRF1 receptors on exploratory behaviour, monoamines and transcription factor AP-2

Pharmacology Biochemistry and Behavior

Volumn 77, Issue 4, 2004, Pages 855-865

  Mällo, Tanel ^a   Berggård, Cecilia ^b   Eller, Marika ^a   Damberg, Mattias ^b   Oreland, Lars ^b   Harro, Jaanus ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Corticotropin releasing factor (CRF); CP 154,526; CRF1 receptor; DSP 4; Exploratory behaviour; Locus coeruleus (LC); Monoamine neurochemistry; Transcription factor AP 2

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ANXIOLYTIC AGENT; BRAIN MONOAMINE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; NORADRENALIN; TRANSCRIPTION FACTOR AP 2;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENERVATION; DRUG EFFECT; EXPLORATORY BEHAVIOR; FRONTAL CORTEX; HABITUATION; HIPPOCAMPUS; LOCUS CERULEUS; MALE; MAZE TEST; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; DNA-BINDING PROTEINS; EXPLORATORY BEHAVIOR; MALE; PYRIMIDINES; PYRROLES; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 1942455343     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.02.016     Document Type: Article

References (39)

1. Arborelius L., Skelton K.H., Thrivikrman K.V., Plotsky P.M., Schulz D.W., Owens M.J. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J. Pharmacol. Exp. Ther. 294:2000;588-597.
2. Buwalda B., Van Kalkeren A.A., de Boer S.F., Koolhaas J.M. Behavioral and physiological consequences of repeated daily intracerebroventricular injection of corticotropin-releasing factor in the rat. Psychoneuroendocrinology. 23:1997;205-218.
3. Contarino A., Dellu F., Koob G.F., Smith G.W., Lee K.F., Vale W.et al. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. 835:1999;1-9.
4. Curtis A.L., Lechner S.M., Pavcovich L.A., Valentino R.J. Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. J. Pharmacol. Exp. Ther. 281:1997;163-172.
5. Damberg M., Ekblom J., Oreland L. Chronic pharmacological treatment with certain antidepressants alters the expression and DNA-binding activity of transcription factor AP-2. Life Sci. 68:2000;669-678.
6. Damberg M., Garpenstrand H., Hallman J., Oreland L. Genetic mechanisms of behavior - don't forget about the transcription factors. Mol. Psychiatry. 6:2001;503-510.
7. Damberg M., Eller M., Tõnissaar M., Oreland L., Harro J. Levels of transcription factors AP2α and AP2β in the brainstem are correlated to monoamine turnover in the rat forebrain. Neurosci. Lett. 313:2001;102-104.
8. Dawson G.R., Tricklebank M.D. Use of the elevated plus-maze in the search for novel anxiolytic agents. Trends Pharmacol. Sci. 16:1995;33-36.
9. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1983;1475-1489.
10. Eghbal-Ahmadi M., Hatalski C.G., Avishai-Eliner S., Baram T.Z. Corticotropin releasing factor receptor type II (CRF2) messenger ribonucleic acid levels in the hypothalamic ventromedial nucleus of the infant rat are reduced by maternal deprivation. Endocrinology. 138:1997;5048-5051.
11. Emoto H., Koga C., Ishii H., Yokoo H., Yoshida M., Tanaka M. A CRF antagonist attenuates stress-induced increases in NA turnover in extended brain regions in rats. Brain Res. 627:1993;171-176.
12. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82:1999;1-61.
13. Griebel G., Perrault G., Sanger D.J. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Psychopharmacology. 138:1998;55-66.
14. Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P.et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl))-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotropin-releasing factor 1 receptor antagonist: II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. 301:2002;333-345.
15. Harro J., Oreland L., Vasar E., Bradwejn J. Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. Eur. Neuropsychopharmacol. 5:1995;447-455.
16. Harro J., Tõnissaar M., Eller M. The effects of CRA1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat. Neuropeptides. 35:2001;100-109.
17. Kawahara H., Kawahara Y., Westerink B.H.C. The role of afferents to the locus coeruleus in the handling stress-induced increase in the release of noradrenaline in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain. Eur. J. Pharmacol. 387:2000;279-286.
18. Kim H.S., Hong S.J., LeDoux M.S., Kim K.S. Regulation of the tyrosine hydroxylase and dopamine beta-hydroxylase genes by the transcription factor AP-2. J. Neurochem. 76(1):2001;280-294.
19. 1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats. Eur. J. Pharmacol. 464:2003;127-133.
20. Lowry O.H., Rosebrough N.J., Lewis Farr A., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
21. Lundkvist J., Chai Z., Teheranian R., Hasanvan H., Bartfai T., Jenck F.et al. A non peptidic corticotropin releasing factor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur. J. Pharmacol. 309:1996;195-200.
22. Matto V., Harro J., Allikmets L. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology. 36:1997;389-396.
23. 1 antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology. 25:2001;585-600.
24. 1 receptor antagonist, CRA1000, on locomotor activity and endocrine responses to stress. Eur. J. Pharmacol. 457:2002;201-206.
25. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S.-I., Nakazato A.et al. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. 289:1999;926-935.
26. Otter M.-H., Matto V., Sõukand R., Skrebuhhova T., Allikmets L., Harro J. Characterization of rat exploratory behavior using the exploration box test. Meth. Find. Exp. Clin. Pharmacol. 19:1997;683-691.
27. Paxinos G., Watson C. The rat brain stereotaxic coordinates. 1986;Academic Press, San Diego.
28. Reboucas R.C., Schmidek W.R. Handling and isolation in three strains of rats affect open field, exploration, hoarding and predation. Physiol. Behav. 62:1997;1159-1164.
29. Ren Y., Liao W.S.L. Transcription factor AP-2 functions as a repressor that contributes to the liver-specific expression of serum amyloid A1 gene. J. Biol. Chem. 276:2001;17770-17778.
30. Ross S.B. Long-term effect of N(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurons in the rat brain and heart. Br. J. Pharmacol. 58:1976;521-527.
31. Sauvage M., Steckler T. Detection of corticotropin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic and noradrenergic neurons of the murine basal forebrain and brainstem nuclei-potential implication for arousal and attention. Neuroscience. 104:2001;643-652.
32. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M.et al. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin-releasing factor receptors. Proc. Natl. Acad. Sci. U. S. A. 93:1996;10477-10482.
33. Shepherd J.K., Grewal S.S., Fletcher A., Bill D.J., Dourish C.T. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology. 116:1994;56-64.
34. Sutton R.E., Koob G.F., Le Moal M., Rivier J., Vale W. Corticotropin releasing factor produces behavioural activation in rats. Nature. 297:1982;331-333.
35. 2 receptors in fear and anxiety. Neurosci. Biobehav. Rev. 25:2001;627-636.
36. Takahashi L.K., Ho S.P., Livanov V., Graciani N., Arneric S.P. Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res. 902:2001;135-142.
37. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M.H.M., Stalla G.K.et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 19:1998;162-166.
38. Valentino R.J., Foote S.L., Aston-Jones G. Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res. 270:1983;363-367.
39. Zorrilla E.P., Valdez G.R., Nozulak J., Koob G.F., Markou A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res. 952:2002;188-199.